Dr. Shore Discusses NEJM Studies in Video Series

Aug. 2020

Neal Shore, MD, FACS, Medical Director for the Carolina Urologic Research Center and Past-President of LUGPA, has led an extensive amount of research in the treatment and management of prostate cancer. In a series of interviews with Oncology Tube, Dr. Shore talks about the recent NEJM Studies (Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer, Olaparib for Metastatic Castration-Resistant Prostate Cancer, and Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer):

• Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer
• Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer
• Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer - Common Questions Asked

• Olaparib for Metastatic Castration-Resistant Prostate Cancer
• Olaparib for Metastatic Castration-Resistant Prostate Cancer
• Olaparib for Metastatic Castration-Resistant Prostate Cancer - Common Questions Asked

• Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer
• Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer
• Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer - Common Questions Asked